Fig. 2From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyCumulative disease free survival curve of the study population (n = 30). The median DFS was 14.9 months (95% CI 0–33.8) for the entire patient population with a 3-year DFS of 43.1 ± 9.1%Back to article page